Tuberculosis remains one of the world’s most persistent infectious diseases, and despite decades of available treatments, achieving cure remains a long and winding road. The challenge isn’t just the disease itself – there is also a notable difference in how patients respond to TB drugs. From the early bactericidal activity in the first two weeks to managing drug-resistant strains, TDM offers a path to optimising treatment while minimising toxicity. Yet significant barriers remain, particularly in the low- and middle-income countries where TB burden is highest.
Eight Drugs a Week is supported by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). The personal views of the hosts and guests do not necessarily reflect the position of the Association.
Thi Nguyen is a PhD candidate at Sydney University School of Pharmacy. Originally from Vietnam, a high-TB-burden country, she focuses on developing saliva-based therapeutic drug monitoring to make personalised TB treatment accessible in resource-limited settings.
Marieke Sturkenboom is the recently appointed Laboratory Head at the Clinical Pharmacy and Pharmacology department at the University of Groningen Medical Centre in the Netherlands, with special expertise in TDM and model-informed precision dosing of anti-TB drugs.
We are also joined by Jorie Versmissen, Erasmus Medical Centre, Rotterdam, as co-host.
Listen to this podcast: https://podcasts.apple.com/fr/podcast/eight-drugs-a-week-podcast/id1648539489?i=1000717539174
![]() |
![]() |
The content of the IATDMCT Blog does not necessarily have the endorsement of the Association.